株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界のチロシンキナーゼ阻害剤市場:成長、動向、および予測

Tyrosine Kinase Inhibitors Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 921960
出版日 ページ情報 英文 115 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.51円で換算しております。
世界のチロシンキナーゼ阻害剤市場:成長、動向、および予測 Tyrosine Kinase Inhibitors Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年01月01日 ページ情報: 英文 115 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

当レポートは世界のチロシンキナーゼ阻害剤(TKI)について調査しており、市場機会や動向、成長および阻害要因、タイプ・用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 癌の有病率の増加
    • 研究活動およびチロシンキナーゼ阻害剤への投資の増加
  • 市場の阻害要因
    • 高い治療費
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • タイプ別
    • BCR-ABL
    • 上皮成長因子受容体(EGFR)
    • 血管内皮細胞増殖因子受容体(VEGFR)
    • その他
  • 用途別
    • 慢性骨髄性白血病(CML)
    • 肺癌
    • 乳癌
    • 腎細胞癌
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • AstraZeneca
    • Bayer
    • Boehringer Ingelheim International
    • Bristol-Myers Squibb
    • エーザイ株式会社
    • F. Hoffmann-La Roche
    • Johnson and Johnson
    • Novartis
    • Pfizer

第7章 市場機会および今後の動向

目次
Product Code: 67672

Market Overview

A tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to a protein in a cell. A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases.

Recently, due to the increasing prevalence of cancer incidence globally, the demand for novel therapies for treatment has increased. Theoretically, TKI, which is a small molecule, has many advantages over traditional therapies including ease of oral administration, and the ability to target multiple cellular survival pathways. As a result, many researches are being done in order to find cancer treatment theories that involve TKI. Many drugs involving this pathway are under development. These factors are expected to help the growth of the market.

However, high development cost leads to the higher market price of the drug post-approval. Hence the cost of the drug has been restraining the market growth up to a certain extent.

Scope of the Report

A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades.

In the report, a detailed analysis of the tyrosine kinase inhibitor market is provided. The market is evaluated by collating revenues generated across segments, categorized by type, application and geography.

Key Market Trends

Treatment for Chronic Myeloid Leukaemia is Expected to Dominate the Market

Chronic Myeloid Leukemia (CML) is a cancer of the white blood cells which is characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. The incidence of CML has increased over the course of the past few decades as per research by Taisen Hao et al., published in Nature Research Journal 2019. As per the reports CML cases increased from 4,300 cases in 1998 to 8,430 in 2018, up by 96%, in the United States.

CML is largely treated with targeted drugs called tyrosine-kinase inhibitors (TKIs) which have led to dramatically improved long-term survival rates since the early 2000s. These drugs have said to have revolutionized the treatment of this disease by allowing most patients to have a good quality of life when compared to the former chemotherapy drugs.

Hence, with the growing incidence of CML, the market for tyrosine kinase inhibitors therapies is also expected to increase.

North America is Expected to Dominate the Market

The North American countries including the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development, especially on Cancer. Many companies in these countries have been involved in cancer research. These policies have, hence, encouraged other global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players.

Moreover, the prevalence of cancer is also high in these countries. The prevalence of cancer in the United States (US) is one of the highest in the world. As per a 2018 report by the World Cancer Research Fund International, the prevalence of cancer in the US is 352.2 per 100,000. As per the same report, Canada also has a high prevalence of cancer with 334 per 100,000 Canadians suffering from the dreadful disease. This high prevalence of cancer has increased the economic burden of cancer of the population of this region.

Hence, as high demand is met by the presence of global players in the region, the market is further expected to increase.

Competitive Landscape

The majority of the tyrosine kinase inhibitors therapies are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market grow at a significant rate.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cancer
    • 4.2.2 Growing Research Activities and Investment in Tyrosine Kinase Inhibitors
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Therapy
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 BCR-ABL Tyrosine Kinase Inhibitor
    • 5.1.2 Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
    • 5.1.3 Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
    • 5.1.4 Others
  • 5.2 By Application
    • 5.2.1 Chronic Myeloid Leukemia (CML)
    • 5.2.2 Lung Cancer
    • 5.2.3 Breast Cancer
    • 5.2.4 Renal Cell Cancer
    • 5.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca
    • 6.1.2 Bayer
    • 6.1.3 Boehringer Ingelheim International
    • 6.1.4 Bristol-Myers Squibb
    • 6.1.5 Eisai
    • 6.1.6 F. Hoffmann-La Roche
    • 6.1.7 Johnson and Johnson
    • 6.1.8 Novartis
    • 6.1.9 Pfizer

7 MARKET OPPORTUNITIES AND FUTURE TRENDS